Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

Antonia, 2018, Durvalumab in stage III non-small-cell lung cancer, N Engl J Med, 378, 869 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Spigel, 2022, Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, J Clin Oncol, 40, 1301, 10.1200/JCO.21.01308 Hanna, 2021, Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update, J Clin Oncol, 39, 1040, 10.1200/JCO.20.03570 Hendriks Ramalingam, 2019, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662 Soria, 2017, Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137 Tsuboi, 2022, LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA, Ann Oncol, 33, S808 Felip, 2021, Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial, Lancet, 398, 1344, 10.1016/S0140-6736(21)02098-5 O’Brien, 2022, Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial, Lancet Oncol, 23, 1274, 10.1016/S1470-2045(22)00518-6 Paz-Ares, 2022, Ann Oncol, 33, 451, 10.1016/j.annonc.2022.02.224 Aredo, 2021, Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy, J Thorac Oncol, 16, 1030, 10.1016/j.jtho.2021.01.1628 Hellyer, 2021, Role of consolidation durvalumab in patients with EGFR- and HER2-mutant unresectable stage III NSCLC, J Thorac Oncol, 161, 868, 10.1016/j.jtho.2020.12.020 Lisberg, 2018, A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC, J Thorac Oncol, 13, 1138, 10.1016/j.jtho.2018.03.035 Gettinger, 2016, Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer, J Clin Oncol, 34, 2980, 10.1200/JCO.2016.66.9929 Socinski, 2021, IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC, J Thorac Oncol, 16, 1909, 10.1016/j.jtho.2021.07.009 Nogami, 2022, IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain, J Thorac Oncol, 17, 309, 10.1016/j.jtho.2021.09.014 West, 2019, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 20, 924, 10.1016/S1470-2045(19)30167-6 Lee, 2018, Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis, JAMA Oncol, 4, 210, 10.1001/jamaoncol.2017.4427